Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 812345...Last »

Regeneron’s Eylea combo therapy fails study

Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.

Read More »

Trial Failure Forces Bay Area’s Threshold Pharma to Cut Almost a Quarter of Workforce

Shares of Threshold Pharmaceuticals plunged more than 58 percent in pre-market trading after the company announced it was terminating about one-fourth of its workforce following the failure of its Phase II cancer treatment.

Read More »

Alnylam Falls After Stopping Development of RNAi Liver Disease Candidate ALN-AAT

Alnylam Pharmaceuticals recently presented 10 posters and oral presentations showing the progress of its GalNAc platform and its clinical translation at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Montreal. Included in the presentations was a bit of a bomb – in its Phase I/II study of ALN-AAT to treat AAT deficiency-associated liver disease (alpha-1 liver disease), three patients showed asymptomatic, transient increased liver enzymes. As a result, it has halted.

Read More »

Struggling ImmunoGen Eliminates 17% of Workforce After Strategic Review

After a strategic review of its operations and pipeline, Waltham, Massachusetts-based ImmunoGen announced that it will cut 17 percent of its staff, or 65 jobs.

Read More »

Deaths Lead Boehringer to Cancel Deal With Hanmi

Just a day after Hanmi Pharmaceutical announced a deal with Genentech, Boehringer Ingelheim terminated a license deal because of patient deaths.

Read More »

Alcobra plunges after FDA places hold on ADHD drug

Alcobra Ltd.’s market value more than halved a day after the company said the U.S. Food and Drug Administration had placed a hold on its lead experimental drug.

Read More »

Study finds Zika infects neural cells related to skull formation

The Zika virus can infect and alter cells in the human nervous system that are crucial for formation of bones and cartilage in the skull, a study found.

Read More »

Horizon Pharma to pay Express Scripts $65 million to settle rebate litigation

Horizon Pharma said it would pay pharmacy benefit manager Express Scripts Holding $65 million to settle litigation related to after-market rebates for three of its medicines.

Read More »

Amgen, Arrowhead team up on gene-therapies for heart disease

Amgen Inc. said it would buy a stake in Arrowhead Pharmaceuticals Inc. and collaborate with the company to develop gene-silencing therapies for heart disease.

Read More »

Company Email Format

Create My Faculty Document Write my college paper, please… We acquire numerous similar messages on the daily basis. Today, it is an extremely tough job to be always an effective scholar since instructors assign plenty of undertaking to complete, while learners basically have no time to handle all jobs by the due date.

Read More »

MediGene, bluebird bio: $1 Billion+ Deal

MediGene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion.

Read More »

Hanmi Pharma Inks $910M Deal with Genentech

Genentech, a member of the Roche Group, licensed HM95573 from Seoul, South Korea-based Hanmi Pharmaceutical Co. for a deal that could hit $910 million.

Read More »

TechCrunch: Inspiring a different approach for pharma

Every once in a while it’s refreshing for a healthcare digital strategist or innovation officer to take a close look at how marketing technology is being used outside of pharma.

Read More »

Novo Nordisk to ax 1,000 jobs in cost-cutting drive

The world’s largest insulin maker, Novo Nordisk, is cutting 1,000 jobs as a part of a plan to reduce costs as it faces a challenging environment in 2017, especially in the large U.S. market.

Read More »

Actelion to investigate all-oral MS combination therapy

Swiss biotech group Actelion Ltd. will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), calling it the first study of this approach for treating the neurological disorder.

Read More »

FDA approves Medtronic’s ‘artificial pancreas’ for diabetes

Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.

Read More »

In-office tests may detect hip tendon problems before MRI

Two simple tests that can be done in a doctor’s office may be able to rule in or out a painful hip condition that is usually hard to diagnose without magnetic resonance imaging (MRI), according to a small study.

Read More »

Senators ask Justice Dept to consider probe of EpiPen Medicaid classification

U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department to investigate whether Mylan NV may have misclassified its EpiPen in order to pay lower rebates to the states.

Read More »

Boehringer boosts immune-oncology pipeline

Boehringer Ingelheim and ViraTherapeutics will jointly develop a next-generation oncolytic virus therapy platform and investigate ViraTherapeutics’ lead candidate.

Read More »

Biogen to Test Anavex’s Lead Drug Candidate

Biogen will test Anavex Life Sciences’ lead drug candidate, ANAVEX 2-73, in an oligodendrocyte precursor cell (OPC) differentiation assay.

Read More »

Page 1 of 812345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom